Shiraz Halloush
Biographic Data
| ID | 9997293 |
|---|---|
| NAME | Shiraz Halloush |
| GIVEN NAMES | Shiraz |
| FAMILY NAME | Halloush |
| SIGNATURE | HALLOUSH S |
| AFFILIATIONS | Therapeutics Clinical Research |
| VERIFIED | No |
| TOTAL WORKS | 1 |
| TOTAL CITATIONS | 0 |
| AUTHOR COUNT | 1 |
| EDITOR COUNT | 0 |
| FIRST PUBLICATION YEAR | 2026 |
| LATEST PUBLICATION YEAR | 2026 |
| H-INDEX | 0 |
Budget impact analysis of the introduction of ranibizumab’s biosimilar to the Jordanian joint procurement system
Introduction: The adoption of biologic therapies imposes a substantial financial burden on the Jordanian healthcare system. ranibizumab is prescribed for various retinal disorders, and its associated costs are considerable. The introduction of biosimilars is beneficial in retaining desired clinical parameters while providing cost relief and enhanced access to patients. Objective: To examine the budget impact and expanded access of switching to ra…
No prominent works on this page.
Budget impact analysis of the introduction of ranibizumab’s biosimilar to the Jordanian joint procurement system
Introduction: The adoption of biologic therapies imposes a substantial financial burden on the Jordanian healthcare system. ranibizumab is prescribed for various retinal disorders, and its associated costs are considerable. The introduction of biosimilars is beneficial in retaining desired clinical parameters while providing cost relief and enhanced access to patients. Objective: To examine the budget impact and expanded access of switching to ra…
Aflibercept (1 works) · Biosimilar (1 works) · Biosimilars and Bioanalytical Methods (1 works) · Health Systems, Economic Evaluations, Quality of Life (1 works) · Market share (1 works) · Pharmaceutical Economics and Policy (1 works) · Procurement (1 works) · Ranibizumab (1 works) · Reimbursement (1 works)